贝伐单抗治疗早产儿视网膜病变后视网膜血流量减少

IF 3.2 Q1 OPHTHALMOLOGY

Ophthalmology science Pub Date : 2025-06-16 DOI:10.1016/j.xops.2025.100857

Joyce Wang BS , Shaiza Mansoor BS , Jeong-Yoon Wu BS , Christina Kilby BS , He Forbes MS , Ria Kapoor BS , Sarah Ward , Jason Zhou BS , Kristin Williams RN , Moran Roni Levin MD , Sripriya Sundararajan MD , Larry Magder PhD , Avigyan Sinha PhD , Abhishek Rege PhD , Janet L. Alexander MD, MS

{"title":"贝伐单抗治疗早产儿视网膜病变后视网膜血流量减少","authors":"Joyce Wang BS , Shaiza Mansoor BS , Jeong-Yoon Wu BS , Christina Kilby BS , He Forbes MS , Ria Kapoor BS , Sarah Ward , Jason Zhou BS , Kristin Williams RN , Moran Roni Levin MD , Sripriya Sundararajan MD , Larry Magder PhD , Avigyan Sinha PhD , Abhishek Rege PhD , Janet L. Alexander MD, MS","doi":"10.1016/j.xops.2025.100857","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To compare total retinal blood flow (TRBF) rates before and after retinopathy of prematurity (ROP) treatment with intravitreal bevacizumab using laser speckle contrast imaging (LSCI).</div></div><div><h3>Design</h3><div>A prospective cohort study.</div></div><div><h3>Participants</h3><div>Twenty-five eyes from 14 premature infants in the neonatal intensive care unit receiving intravitreal bevacizumab for treatment-requiring ROP.</div></div><div><h3>Methods</h3><div>Total retinal blood flow was measured using LSCI longitudinally before and after bevacizumab treatment. Subject characteristics and clinical ROP features, including the need for ROP retreatment, were included in regression analysis using generalized estimating equations to account for 2 eyes per subject and longitudinal measures over time.</div></div><div><h3>Main Outcome Measures</h3><div>The main outcome measure was TRBF, which includes components of peak, mean, and dip over the cardiac cycle.</div></div><div><h3>Results</h3><div>Before ROP treatment, subjects had a peak TRBF of 11.1 ± 2.9 a.u. compared to 8.6 ± 1.8 a.u. after treatment (mean difference = 2.5 a.u., <em>P</em> < 0.0001). Among eyes that required ROP retreatment earlier (<10 weeks) after initial treatment, the posttreatment peak TRBF was 9.0 ± 1.5 a.u., compared to 7.3 ± 2.2 a.u. for eyes that did not require retreatment in the first 10 weeks after initial bevacizumab injection (mean difference = 1.7 a.u., <em>P</em> = 0.01). Peak TRBF decreased over time after bevacizumab treatment (β = −0.1 a.u./week, <em>P</em> = 0.004).</div></div><div><h3>Conclusions</h3><div>We observed lower TRBF after treatment with intravitreal bevacizumab.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":74363,"journal":{"name":"Ophthalmology science","volume":"5 6","pages":"Article 100857"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retinal Blood Flow Decreases after Treatment with Bevacizumab for Retinopathy of Prematurity\",\"authors\":\"Joyce Wang BS , Shaiza Mansoor BS , Jeong-Yoon Wu BS , Christina Kilby BS , He Forbes MS , Ria Kapoor BS , Sarah Ward , Jason Zhou BS , Kristin Williams RN , Moran Roni Levin MD , Sripriya Sundararajan MD , Larry Magder PhD , Avigyan Sinha PhD , Abhishek Rege PhD , Janet L. Alexander MD, MS\",\"doi\":\"10.1016/j.xops.2025.100857\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To compare total retinal blood flow (TRBF) rates before and after retinopathy of prematurity (ROP) treatment with intravitreal bevacizumab using laser speckle contrast imaging (LSCI).</div></div><div><h3>Design</h3><div>A prospective cohort study.</div></div><div><h3>Participants</h3><div>Twenty-five eyes from 14 premature infants in the neonatal intensive care unit receiving intravitreal bevacizumab for treatment-requiring ROP.</div></div><div><h3>Methods</h3><div>Total retinal blood flow was measured using LSCI longitudinally before and after bevacizumab treatment. Subject characteristics and clinical ROP features, including the need for ROP retreatment, were included in regression analysis using generalized estimating equations to account for 2 eyes per subject and longitudinal measures over time.</div></div><div><h3>Main Outcome Measures</h3><div>The main outcome measure was TRBF, which includes components of peak, mean, and dip over the cardiac cycle.</div></div><div><h3>Results</h3><div>Before ROP treatment, subjects had a peak TRBF of 11.1 ± 2.9 a.u. compared to 8.6 ± 1.8 a.u. after treatment (mean difference = 2.5 a.u., <em>P</em> < 0.0001). Among eyes that required ROP retreatment earlier (<10 weeks) after initial treatment, the posttreatment peak TRBF was 9.0 ± 1.5 a.u., compared to 7.3 ± 2.2 a.u. for eyes that did not require retreatment in the first 10 weeks after initial bevacizumab injection (mean difference = 1.7 a.u., <em>P</em> = 0.01). Peak TRBF decreased over time after bevacizumab treatment (β = −0.1 a.u./week, <em>P</em> = 0.004).</div></div><div><h3>Conclusions</h3><div>We observed lower TRBF after treatment with intravitreal bevacizumab.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>\",\"PeriodicalId\":74363,\"journal\":{\"name\":\"Ophthalmology science\",\"volume\":\"5 6\",\"pages\":\"Article 100857\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666914525001551\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666914525001551","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的比较贝伐单抗玻璃体内治疗早产儿视网膜病变（ROP）前后视网膜总血流量（TRBF）的变化。设计前瞻性队列研究。参与者：来自新生儿重症监护病房的14名早产儿的25只眼睛接受玻璃体内贝伐单抗治疗所需的ROP。方法采用LSCI纵向测量贝伐单抗治疗前后视网膜总血流量。受试者特征和临床ROP特征，包括ROP再治疗的需要，被纳入回归分析，使用广义估计方程来解释每个受试者2只眼睛和随时间的纵向测量。主要结局指标主要结局指标是TRBF，包括心脏周期的峰值、平均值和下降分量。结果ROP治疗前TRBF峰值为11.1±2.9 a.u.，治疗后为8.6±1.8 a.u.(平均差异为2.5 a.u., P <；0.0001)。在初始治疗后早期（10周）需要ROP再治疗的眼睛中，治疗后TRBF峰值为9.0±1.5 a.u.，而在初始贝伐单抗注射后前10周不需要再治疗的眼睛的TRBF峰值为7.3±2.2 a.u.（平均差异= 1.7 a.u., P = 0.01）。贝伐单抗治疗后，峰值TRBF随时间下降（β = - 0.1 a.u./周，P = 0.004）。结论玻璃体内贝伐单抗治疗后TRBF降低。财务披露专有或商业披露可在本文末尾的脚注和披露中找到。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Retinal Blood Flow Decreases after Treatment with Bevacizumab for Retinopathy of Prematurity

Purpose

To compare total retinal blood flow (TRBF) rates before and after retinopathy of prematurity (ROP) treatment with intravitreal bevacizumab using laser speckle contrast imaging (LSCI).

Design

A prospective cohort study.

Participants

Twenty-five eyes from 14 premature infants in the neonatal intensive care unit receiving intravitreal bevacizumab for treatment-requiring ROP.

Methods

Total retinal blood flow was measured using LSCI longitudinally before and after bevacizumab treatment. Subject characteristics and clinical ROP features, including the need for ROP retreatment, were included in regression analysis using generalized estimating equations to account for 2 eyes per subject and longitudinal measures over time.

Main Outcome Measures

The main outcome measure was TRBF, which includes components of peak, mean, and dip over the cardiac cycle.

Results

Before ROP treatment, subjects had a peak TRBF of 11.1 ± 2.9 a.u. compared to 8.6 ± 1.8 a.u. after treatment (mean difference = 2.5 a.u., P < 0.0001). Among eyes that required ROP retreatment earlier (<10 weeks) after initial treatment, the posttreatment peak TRBF was 9.0 ± 1.5 a.u., compared to 7.3 ± 2.2 a.u. for eyes that did not require retreatment in the first 10 weeks after initial bevacizumab injection (mean difference = 1.7 a.u., P = 0.01). Peak TRBF decreased over time after bevacizumab treatment (β = −0.1 a.u./week, P = 0.004).